

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	DEC 01	ChemPort single article sales feature unavailable
NEWS	3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS	4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS	5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS	6	JUN 29	EFFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS	7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS	8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS	9	JUL 27	CA/CAPLUS enhanced with new citing references
NEWS	10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS	11	JUL 21	USGENE adds bibliographic and sequence information
NEWS	12	JUL 28	EFFULL adds first-page images and applicant-cited references
NEWS	13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS	14	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	15	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	16	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	17	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents
NEWS	18	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	19	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS EXPRESS	MAY 26 09	CURRENT WINDOWS VERSION IS V8.4, AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 16:05:32 ON 16 SEP 2009

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 16:06:08 ON 16 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 SEP 2009 HIGHEST RN 1184832-01-6

DICTIONARY FILE UPDATES: 15 SEP 2009 HIGHEST RN 1184832-01-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10758589\_NEW\_20080624.str



chain nodes :

7 8 9 10 11 12 13 14 15 22 23 24 25

ring nodes :

1 2 3 4 5 6 16 17 18 19 20 21

chain bonds :

6-7 7-8 7-24 8-9 9-10 10-11 10-22 11-12 12-13 12-23 13-14 14-15 15-16

15-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

exact/norm bonds :

7-8 7-24 8-9 9-10 10-22 12-13 12-23 13-14 14-15 15-25

exact bonds :

6-7 10-11 11-12 15-16

normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom  
19:Atom 20:Atom 21:Atom 22:CLASS 23:CLASS 24:CLASS 25:CLASS

L1 STRUCTURE UPLOADED

=> s l1 sss

SAMPLE SEARCH INITIATED 16:06:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 15 TO ITERATE

100.0% PROCESSED 15 ITERATIONS 4 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 68 TO 532  
PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	0.70

FILE 'CAPLUS' ENTERED AT 16:06:35 ON 16 SEP 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Sep 2009 VOL 151 ISS 12

FILE LAST UPDATED: 15 Sep 2009 (20090915/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s l2

L3 16 L2

=> s l3 and (?cancer? or ?tumor? or ?tumeur? or ?neoplasm?)

471949 ?CANCER?

744771 ?TUMOR?

6557 ?TUMOUR?

6557 ?TUMOUR?

745154 ?TUMOR?

(?TUMOR? OR ?TUMOUR?)

6557 ?TUMOUR?

744771 ?TUMOR?

744771 ?TUMOR?

745154 ?TUMOUR?

(?TUMOUR? OR ?TUMOR?)

579055 ?NEOPLASM?

L4 15 L3 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 15 DUP REM L4 (0 DUPLICATES REMOVED)

=> d l5 1-15 ibib abs hitstr

L5 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2009:179762 CAPLUS

DOCUMENT NUMBER: 150:229666

TITLE: Hydrazides and related compounds for treating proliferative disorders

INVENTOR(S): Sun, Lijun; Jiang, Jun

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 140pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2009020631	A2	20090212	WO 2008-US9474	20080807
WO 2009020631	A3	20090326		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			


PRIORITY APPLN. INFO.: US 2007-963816P P 20070807  
 OTHER SOURCE(S): MARPAT 150:229666

AB Disclosed are compds. and methods of using compds. of the invention for treating a subject with a proliferative disorder, e.g. cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer cell induction. Also, disclosed are pharmaceutical compns. comprising compds. of the invention and a pharmaceutically acceptable carrier. Preparation of N1-acetyl-N'1,N'3-dimethyl-N'1,N'3-di(phenylcarbonothioyl)malonohydrazide is described.

IT 488833-02-9D, derivs.  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (hydrazides and related compds. for treating proliferative disorders)

RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



L5 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2008:285694 CAPLUS

DOCUMENT NUMBER: 148:299878

TITLE: Combination with bis(thiohydrazide amides) for treating cancer

INVENTOR(S): Koya, Keizo

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 125pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008027445	A2	20080306	WO 2007-US19021	20070830
WO 2008027445	A3	20080626		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA AU 2007290490 A1 20080306 AU 2007-290490 20070830 US 20080119440 A1 20080522 US 2007-897538 20070830 EP 2076254 A2 20090708 EP 2007-837506 20070830				

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,  
AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.:

US 2006-841570P

P 20060831

WO 2007-US19021

W 20070830


OTHER SOURCE(S): MARPAT 148:299878

AB Disclosed herein are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with hyperthermia treatment. Also disclosed are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with radiotherapy.

IT 488833-02-9 874477-65-3 1008758-35-7  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination with bis(thiohydrazide amides) for treating cancer)


RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 874477-65-3 CAPLUS


CN Propanedioic acid, 1,3-bis[2-ethyl-2-(phenylthioxomethyl)hydrazide], sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 1008758-35-7 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(4-methoxyphenyl)thioxomethyl]-2-methylhydrazide], potassium salt (1:2) (CA INDEX NAME)



● 2 K

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)

L5 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2009 ACS ON STN  
ACCESSION NUMBER: 2008:255663 CAPLUS  
DOCUMENT NUMBER: 148:299870  
TITLE: Treating melanoma with bis(thiohydrazide amides)  
INVENTOR(S): McLeod, Matthew  
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
SOURCE: PCT Int. Appl., 155pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008024305	A2	20080228	WO 2007-US18381	20070820
WO 2008024305	A3	20080619		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA AU 2007288340 A1 20080228 AU 2007-288340 20070820 US 20080226588 A1 20080918 US 2007-894270 20070820 EP 2061451 A2 20090527 EP 2007-837061 20070820 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				


PRIORITY APPLN. INFO.: US 2006-838977P P 20060821  
WO 2007-US18381 W 20070820

OTHER SOURCE(S): MARPAT 148:299870


AB Disclosed herein are methods of treating lentigo maligna, superficial spreading malignant melanoma, acral lentiginous malignant melanoma or nodular malignant melanoma with bis(thio-hydrazide amides) represented or pharmaceutically acceptable salts thereof, pharmaceutical compns. comprising these bis(thio-hydrazide amides) and compns. comprising these bis(thiohydrazide)amides and one or more anticancer agent.

IT 488833-02-9 874477-65-3 1008758-35-7  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(treating melanoma with (thiohydrazide amides) and combination with

other agents)  
 RN 488833-02-9 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)




RN 874477-65-3 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-ethyl-2-(phenylthioxomethyl)hydrazide], sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 1008758-35-7 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-[(4-methoxyphenyl)thioxomethyl]-2-methylhydrazide], potassium salt (1:2) (CA INDEX NAME)



● 2 K

L5 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:255437 CAPLUS  
 DOCUMENT NUMBER: 148:299869  
 TITLE: Treating melanoma with bis(thiohydrazide amides)  
 INVENTOR(S): Williams, Martin; McLeod, Matthew; Koya, Keizo  
 PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------



WO 2008024301	A2	20080228	WO 2007-US18357	20070820
WO 2008024301	A3	20080710		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2007288336	A1	20080228	AU 2007-288336	20070820
US 20080176828	A1	20080724	US 2007-894261	20070820
EP 2063878	A2	20090603	EP 2007-811433	20070820
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS			

PRIORITY APPLN. INFO.:

US 2006-838986P	P	20060821
WO 2007-US18357	W	20070820


OTHER SOURCE(S): MARPAT 148:299869

AB Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented or pharmaceutically acceptable salts thereof, pharmaceutical compns. comprising these bis(thio-hydrazide amides) and compns. comprising these bis(thiohydrazide)amides and one or more anti cancer agent.

IT 488833-02-9 874477-65-3 1008758-35-7  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (treating melanoma with (thiohydrazide amides) and combination with other agents)


RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)




RN 874477-65-3 CAPLUS

CN Propanedioic acid, 1,3-bis[2-ethyl-2-(phenylthioxomethyl)hydrazide], sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 1008758-35-7 CAPLUS  
CN Propanedioic acid, 1,3-bis[2-[(4-methoxyphenyl)thioxomethyl]-2-methylhydrazide], potassium salt (1:2) (CA INDEX NAME)



● 2 K

L5 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:256009 CAPLUS  
DOCUMENT NUMBER: 148:299872  
TITLE: Bis(thiohydrazide amide) combination with immunotherapy for treating cancer  
INVENTOR(S): Jacobson, Eric  
PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
SOURCE: PCI Int. Appl., 143pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008024299	A2	20080228	WO 2007-US18354	20070820
WO 2008024299	A3	20080417		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007288334	A1	20080228	AU 2007-288334	20070820
EP 2059236	A2	20090520	EP 2007-811430	20070820
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,				

AL, BA, HR, MK, RS  
PRIORITY APPLN. INFO.:

US 2006-839113P P 20060821  
WO 2007-US18354 W 20070820


OTHER SOURCE(S): MARPAT 148:299872

AB The invention discloses methods for treating an immunosensitive cancer with bis(thiohydrazide amides), or pharmaceutically acceptable salts thereof, and an immunotherapy. Comps. of the invention include e.g. PhC(S)N(Me)NHC(O)CH<sub>2</sub>C(O)NHN(Me)C(S)Ph.

IT 488833-02-9 874477-65-3 1008758-35-7  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bis(thiohydrazide amide) combination with immunotherapy for treatment of cancer)


RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 874477-65-3 CAPLUS


CN Propanedioic acid, 1,3-bis[2-ethyl-2-(phenylthioxomethyl)hydrazide], sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 1008758-35-7 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(4-methoxyphenyl)thioxomethyl]-2-methylhydrazide], potassium salt (1:2) (CA INDEX NAME)




● 2 K

DOCUMENT NUMBER: 148:276787  
 TITLE: Therapeutic bis(thiohydrazide amides) for inhibiting angiogenesis  
 INVENTOR(S): Barsoum, James; Foley, Kevin  
 PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
 SOURCE: PCT Int. Appl., 50pp.  
 CODEN: P1XXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008024298	A1	20080228	WO 2007-US18353	20070820
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2006-838956P P 20060821  
 OTHER SOURCE(S): MARPAT 148:276787  
 GI




AB Disclosed herein are methods of inhibiting angiogenesis in a subject in need thereof with bis(thio-hydrazide amides) represented by general formula I, wherein Y is a covalent bond or an (un)substituted straight chained hydrocarbyl group, or Y, taken together with both >C=Z groups is an (un)substituted aromatic group; R1-R4 are H, (un)substituted aliphatic or aryl group, or R1 plus R3 and R2 plus R4 are part of a nonarom. heterocyclic ring optionally fused to an aromatic ring; R7-R8 are independently H, (un)substituted aliphatic or aryl group; and Z is O or S.

IT 488833-02-9 874477-65-3 1008758-35-7  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (bis(thiohydrazide amides) for inhibiting angiogenesis and use in therapy)  
 RN 488833-02-9 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 874477-65-3 CAPLUS


CN Propanedioic acid, 1,3-bis[2-ethyl-2-(phenylthioxomethyl)hydrazide], sodium salt (1:2) (CA INDEX NAME)



● 2 Na

RN 1008758-35-7 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(4-methoxyphenyl)thioxomethyl]-2-methylhydrazide], potassium salt (1:2) (CA INDEX NAME)



● 2 K

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2009 ACS ON STN

ACCESSION NUMBER: 2006:1122626 CAPLUS

DOCUMENT NUMBER: 145:449186

TITLE: Combination cancer therapy with bis(thiohydrazide) amide compounds and taxanes

INVENTOR(S): Dahl, Thomas A.; McLeod, Matthew

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 63pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113695	A1	20061026	WO 2006-US14531	20060413

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2006236378 A1 20061026 AU 2006-236378 20060413  
CA 2604907 A1 20061026 CA 2006-2604907 20060413  
EP 1877048 A1 20080116 EP 2006-750538 20060413

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

JP 2008536875 T 20080911 JP 2008-506821 20060413  
ZA 2007008703 A 20081126 ZA 2007-8703 20071011  
MX 2007012688 A 20080314 MX 2007-12688 20071012  
US 20090137682 A1 20090528 US 2008-918357 20080825

PRIORITY APPLN. INFO.: US 2005-672139P P 20050415  
WO 2006-US14531 W 20060413

OTHER SOURCE(S): MARPAT 145:449186

AB A method of treating a subject with cancer includes co-administering to the subject over 3-5 wk, a taxane in an amount of between about 243-315  $\mu\text{mol}/\text{m}^2$  (e.g., equivalent to paclitaxel in about 210-270  $\text{mg}/\text{m}^2$ ); and a bis(thiohydrazide amide) in an amount between about 1473-1722  $\mu\text{mol}/\text{m}^2$ . (e.g. PhC(S)N(Me)NHC(O)CH<sub>2</sub>C(O)NHN(Me)C(S)Ph in about 590-690  $\text{mg}/\text{m}^2$ ). The bis(thiohydrazide amide) is represented by R1C(S)N(R3)N(R7)C(Z)YC(Z)N(R8)N(R4)C(S)R2 [Y = covalent bond, (un)substituted straight chain hydrocarbyl, or C(Z)YC(Z) forms (un)substituted aromatic group; R1-R4 = H, (un)substituted aliphatic group, (un)substituted aryl group, etc.; R7, R8 = H, (un)substituted aliphatic group, (un)substituted aryl group; Z = O, S].


IT 488833-02-9 488833-02-9D, disodium or dipotassium salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bis(thiohydrazide) amide compound-taxane combination for cancer treatment)


RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1123448 CAPLUS  
 DOCUMENT NUMBER: 145:449209  
 TITLE: Methods of increasing natural killer cell activity for therapy  
 INVENTOR(S): Barsoum, James; Du, Zhenjian  
 PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA  
 SOURCE: PCT Int. Appl., 66pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113572	A1	20061026	WO 2006-US14320	20060413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2006236534 A1 20061026 AU 2006-236534 20060413 CA 2603314 A1 20061026 CA 2006-2603314 20060413 EP 1871350 A1 20080102 EP 2006-750374 20060413 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU JP 2008536870 T 20080911 JP 2008-506798 20060413 US 20090042991 A1 20090212 US 2008-918354 20080212 PRIORITY APPLN. INFO.: US 2005-671910P P 20050415 WO 2006-US14320 W 20060413				


OTHER SOURCE(S): MARPAT 145:449209  
 AB Methods of employing bis(thio-hydrazide amides) to increase natural killer (NK) cell activity in a subject in need thereof, e.g., a subject with an infection or an immunodeficiency, are provided such that the disorder is not cancer, a proliferative cell disorder, a non-infective heat shock protein 70 (Hsp70) responsive disorder, or a proteasome-inhibitor responsive disorder. Typically, a subject, e.g., a human, can be in need of increased NK cell activity has an immunodeficiency or is treated for an infection (e.g., a bacterial, viral, fungal, or parasite infection, or a combination thereof). The method includes administering to the subject an

effective amount of a compound represented by  
 $R1(C:S)NR3NR7(C:Z)Y(C:Z)NR8NR4(C:S)R2$  where Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both  $>C=Z$  groups to which it is bonded, is an optionally substituted aromatic group; R1-R4 are independently -H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring; R7-R8 are independently -H, an optionally substituted aliphatic group, or an optionally substituted aryl group; Z is O or S.

IT 488833-02-9 488833-02-9D, disodium or dipotassium salts  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methods of increasing natural killer cell activity for therapy of infection or immunodeficiency using bis(thiohydrazide)amides)  
 RN 488833-02-9 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 488833-02-9 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1124931 CAPLUS  
 DOCUMENT NUMBER: 145:449193  
 TITLE: Natural killer cell activity-based methods for determining prognosis for patients undergoing cancer therapy  
 INVENTOR(S): Barsoum, James; Du, Zhenjian; Dahl, Thomas A.; McLeod, Matthew  
 PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA



SOURCE: PCT Int. Appl., 82 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006113493	A2	20061026	WO 2006-US14186	20060413
WO 2006113493	A3	20081231		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-671833P P 20050415


OTHER SOURCE(S): MARPAT 145:449193

AB A method of determining a prognosis for a subject undergoing cancer therapy with an agent that activates heat shock protein 70 (Hsp70) includes comparing natural killer (NK) cell activity in a test sample with NK cell activity in a control sample. The control sample can be taken from the subject before dosing with the agent and the test sample can be taken from the subject after dosing with the agent. An increase in NK cell activity in the test sample compared with the control sample can indicate an improved prognosis.

IT 488833-02-9 488833-02-9D, disodium or dipotassium salts  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (natural killer cell activity-based methods for determining prognosis for patients undergoing cancer therapy)


RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)

L5 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:494013 CAPLUS

DOCUMENT NUMBER: 145:1005

TITLE: Bis(thio-hydrazide amides) for increasing Hsp70 expression

INVENTOR(S): Barsoum, James

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006055747	A2	20060526	WO 2005-US41750	20051117
WO 2006055747	A3	20061005		
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
AU 2005306471	A1	20060526	AU 2005-306471	20051117
CA 2587598	A1	20060526	CA 2005-2587598	20051117
US 20060142386	A1	20060629	US 2005-281923	20051117
EP 1827410	A2	20070905	EP 2005-824349	20051117
<p>R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU</p>				
JP 2008520697	T	20080619	JP 2007-543254	20051117
PRIORITY APPLN. INFO.:			US 2004-629595P	P 20041119
			WO 2005-US41750	W 20051117


OTHER SOURCE(S): MARPAT 145:1005

AB The present invention discloses a method of treating a Hsp70-responsive disorder by which a subject is administered an effective amount of a Bis(thio-hydrazide amide) compound


IT 488833-02-9 874477-65-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(thiohydrazide amides for increasing hsp70 expression)

RN 488833-02-9 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 874477-65-3 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-ethyl-2-(phenylthioxomethyl)hydrazide], sodium salt (1:2) (CA INDEX NAME)



● 2 Na

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:75829 CAPLUS

DOCUMENT NUMBER: 144:170795

TITLE: Preparation of bis(thiohydrazide amide) salts for treatment of cancer

INVENTOR(S): Kostik, Elena; Vaghefi, Farid; Liang, Guiqing; Koya, Keizo; Sun, Lijun; Tatsuta, Noriaki; Chen, Shoujun; Inoue, Takayo; Xia, Zhi-Qiang

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006009940	A1	20060126	WO 2005-US21642	20050620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

AU 2005265202	A1	20060126	AU 2005-265202	20050620
CA 2005265202	B2	20090723		
CA 2570698	A1	20060126	CA 2005-2570698	20050620
US 20060135595	A1	20060622	US 2005-157213	20050620
US 7385084	B2	20080610		
EP 1781604	A1	20070509	EP 2005-762347	20050620

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,  
HR, LV, MK, YU

CN 1993318	A	20070704	CN 2005-80026445	20050620
JP 20080504264	T	20080214	JP 2007-518152	20050620
BR 2005012526	A	20080311	BR 2005-12526	20050620
ZA 2006010440	A	20071227	ZA 2006-10440	20061213
MX 2006015126	A	20080911	MX 2006-15126	20061220
IN 2007DN00172	A	20070803	IN 2007-DN172	20070108
NO 2007000378	A	20070316	NO 2007-378	20070119
KR 2007029259	A	20070313	KR 2007-701513	20070122
US 20080269340	A1	20081030	US 2008-148312	20080418
US 7579503	B2	20090825		

PRIORITY APPLN. INFO.:

US 2004-582596P	P	20040623
US 2005-681368P	P	20050516
US 2005-157213	A1	20050620
WQ 2005-US21642	W	20050620

OTHER SOURCE(S): MARPAT 144:170795

AB R1CSR3N3C(Z-)YC(Z-)NNR4CSR2.2M+ [Y = bond, (substituted) hydrocarbylene; R1-R4 = H, (substituted) aliphatic, aryl; R1R3, R2R4 = atoms to form non-aromatic heterocyclic ring optionally fused to aromatic ring; Z = O, S; M+

pharmaceutically acceptable cation], were prepared. Thus,  $(\text{PhCSNMeNHCO})_2\text{CH}_2$  was added to aqueous NaOH followed by freeze drying to give  $[\text{PhCSNMeN:C(ONa)}]_2\text{CH}_2$ . The latter showed  $\text{H}_2\text{O}$  soly of  $>1000 \text{ mg/mL}$ .

IT 874477-65-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of bis(thiohydrazide amide) salts for treatment

of cancer)

RN 874477-65-3 CAPLUS

CN Propanedioic acid, 1,3-bis[2-ethyl-2-(phenylthioxomethyl)hydrazide], sodium salt (1:2) (CA INDEX NAME)




●2 Na

IT 488833-02-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of bis(thiohydrazide amide) salts for treatment of

cancer)  
 RN 488833-02-9 CAPLUS  
 CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD  
 (4 CITINGS)  
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:633518 CAPLUS

DOCUMENT NUMBER: 141:173877

TITLE: A preparation of malonyl dihydrazide derivatives,  
 useful for the treatment of multi-drug resistant  
 cancer

INVENTOR(S): Koya, Keizo; Sun, Lijun; Wu, Yaming; Korbut, Timoty;  
 Zhou, Dan; Du, Zhenjian; Chen, Shoujun; Tatsuta,  
 Noriaki; Liang, Guiqing; Ono, Mitsunori

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064826	A1	20040805	WO 2004-US1089	20040115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
AU 2004206865	A1	20040805	AU 2004-206865	20040115
AU 2004206865	B2	20060713		
CA 2512797	A1	20040805	CA 2004-2512797	20040115
US 20040225016	A1	20041111	US 2004-758589	20040115
EP 1583524	A1	20051012	EP 2004-702560	20040115
EP 1583524	B1	20060823		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515626	T	20060601	JP 2006-500976	20040115
AT 336991	T	20060915	AT 2004-702560	20040115
ES 2271839	T3	20070416	ES 2004-702560	20040115
HK 1084024	A1	20070119	HK 2006-104252	20060407
AU 2006228035	A1	20061102	AU 2006-228035	20061011
PRIORITY APPLN. INFO.:			US 2003-440406P	P 20030115
			AU 2004-206865	A3 20040115
			WO 2004-US1089	W 20040115

OTHER SOURCE(S): MARPAT 141:173877

GI




AB One embodiment of the present invention is a method of treating a subject with a multi-drug resistant cancer. The method comprises administering to the subject an effective amount of a compound represented by formula I [wherein: Y is a covalent bond or (un)substituted straight chained hydrocarbaryl group, or, Y, taken together with both >C=Z groups to which it is bonded, is (un)substituted aromatic group; R1-R4 are independently H, aliphatic group, substituted aliphatic group, or aryl group, etc.; R5 and R6 are independently H, aliphatic group, substituted aliphatic group, (un)substituted aryl group; Z is O or S]. For instance, malonyl dihydrazide derivative II (IC50 = 0.005  $\mu$ M, multi-drug cell line MES-SA/DX5) was prepared via amidation of malonic acid by PhC(:S)N(Me)NH2 with a yield of 80% (example 4).

IT 488833-02-9P 488833-21-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of malonyl dihydrazide derivs. useful for treating multi-drug resistant cancer)


RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 488833-21-2 CAPLUS

CN Propanedioic acid, 1,3-bis[2-(2-methylphenyl)-2-phenylthioxomethylhydrazide] (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD  
(7 CITINGS)  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:58057 CAPLUS

DOCUMENT NUMBER: 138:122398

TITLE: Preparation of bis(thiohydrazide) derivatives as taxol  
enhancer compounds

INVENTOR(S): Koya, Keizo; Sun, Lijun; Chen, Shoujun; Tatsuta,  
Noriaki; Wu, Yaming; Ono, Mitsunori

PATENT ASSIGNEE(S): SBR Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006430	A1	20030123	WO 2002-US21717	20020710
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2455453	A1	20030123	CA 2002-2455453	20020710
AU 2002316626	A1	20030129	AU 2002-316626	20020710
AU 2002316626	B2	20050602		
EP 1406869	A1	20040414	EP 2002-746947	20020710
EP 1406869	B1	20060913		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002011227	A	20040810	BR 2002-11227	20020710
JP 2004534848	T	20041118	JP 2003-512202	20020710
CN 1553895	A	20041208	CN 2002-817733	20020710
CN 100348580	C	20071114		
NZ 530963	A	20050826	NZ 2002-530963	20020710
AT 339402	T	20061015	AT 2002-746947	20020710
EP 1731148	A1	20061213	EP 2006-19066	20020710
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI			
ES 2271292	T3	20070416	ES 2002-746947	20020710
NO 2004000095	A	20040223	NO 2004-95	20040109

MX	2004000244	A	20050307	MX	2004-244	20040109
ZA	2004001051	A	20050622	ZA	2004-1051	20040209
ZA	2004001054	A	20050622	ZA	2004-1054	20040209
HK	1060115	A1	20061124	HK	2004-103011	20040429
US	20060116374	A1	20060601	US	2005-244427	20051005
US	7368473	B2	20080506			
US	20060122183	A1	20060608	US	2005-244324	20051005
US	7345094	B2	20080318			
US	20080214655	A1	20080904	US	2008-9641	20080118
US	20080242702	A1	20081002	US	2008-77729	20080320
PRIORITY APPLN. INFO.:				US	2001-304252P	P 20010710
				US	2002-361946P	P 20020306
				US	2002-361936P	P 20020306
				EP	2002-746947	A3 20020710
				US	2002-193075	A1 20020710
				US	2002-193639	A1 20020710
				WO	2002-US21717	W 20020710
				US	2004-803798	A1 20040318
				US	2004-846152	A1 20040514
				US	2005-244324	A1 20051005
				US	2005-244427	A3 20051005

OTHER SOURCE(S): MARPAT 138:122398  
GI




AB Title compds. I [Y = bond, phenylene, hydrocarbonyl or taken together with both >C=Z groups is aromatic; R1-2 = (un)substituted aryl; R3-4 = H, alkyl, aryl; R5-6 = H, alkyl, aryl; Z = O, with provisions] and analogs are prepared. For instance, thiobenzoic acid N-methylhydrazide (preparation given) was added to malonyl dichloride to give bis-hydrazide II. The combination of example compds. and paclitaxel administered to mice with tumors (MDA-435) resulted in greater tumor reduction than either active component given alone.

IT 488833-02-9P 488833-21-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of bis(thiohydrazide) derivs. as taxol enhancer compds. for the treatment of cancer)

RN 488833-02-9 CAPLUS


CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)





RN 488833-21-2 CAPLUS

CN Propanedioic acid, 1,3-bis[2-(2-methylphenyl)-2-(phenylthioxomethyl)hydrazide] (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)  
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:58056 CAPLUS

DOCUMENT NUMBER: 138:122397

TITLE: Process for the preparation of bis(thiohydrazide) derivatives used as Taxol enhancers

INVENTOR(S): Chen, Shoujun; Sun, Lijun; Xia, Zhi-Qiang; Koya, Keizo; Ono, Mitsunori

PATENT ASSIGNEE(S): SBR Pharmaceuticals Corp., USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003006429	A1	20030123	WO 2002-US21716	20020710
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
TW 252847	B	20060411	TW 2002-91115205	20020709
CA 2453415	A1	20030123	CA 2002-2453415	20020710
AU 2002316625	A1	20030129	AU 2002-316625	20020710
AU 2002316625	B2	20060525		

US 20030069225	A1	20030410	US 2002-193076	20020710
US 6825235	B2	20041130		
EP 1406868	A1	20040414	EP 2002-746946	20020710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004534847	T	20041118	JP 2003-512201	20020710
CN 1553893	A	20041208	CN 2002-817724	20020710
CN 100398516	C	20080702		
CN 101270069	A	20080924	CN 2008-10092868	20020710
NO 2004000053	A	20040210	NO 2004-53	20040107
MX 2004000245	A	20050307	MX 2004-245	20040109
IN 2004DN00077	A	20060224	IN 2004-DN77	20040112
US 20040229952	A1	20041118	US 2004-807919	20040324
US 7074952	B2	20060711		
US 20060281811	A1	20061214	US 2006-440429	20060524
US 7435843	B2	20081014		
AU 2006203689	A1	20060914	AU 2006-203689	20060824
US 20090005594	A1	20090101	US 2008-231217	20080829
PRIORITY APPLN. INFO.:			US 2001-304318P	P 20010710
			CN 2002-817724	A3 20020710
			US 2002-193076	A1 20020710
			WO 2002-US21716	W 20020710
			US 2004-807919	A1 20040324
			US 2006-440429	A1 20060524
OTHER SOURCE(S):		CASREACT 138:122397; MARPAT 138:122397		
GI				



AB Disclosed is a method of preparing bis(thiohydrazide) I [R1-2 = aliphatic, aryl, etc.; R10 = H, alkyl; Y = bond, hydrocarbyl]. The method comprises reacting a hydrazide with a thionation reagent followed by reaction of the thiohydrazide with Z-C(O)-Y-C(O)-Z or HO-C(O)-Y-C(O)-OH [Z = leaving group; Y is as defined above] and a carboxylic acid activating agent to produce I. For instance, 2,5-dimethoxybenzoic acid is coupled to methylhydrazine (CH<sub>2</sub>Cl<sub>2</sub>, DCC, DMAP); the resulting hydrazide is treated with Lawesson's reagent and the product reacted with 2-methylmalonic acid (DMF, DCC) to give II. I enhance the anti-cancer activity of taxol and analogs thereof.


IT 488833-02-9P 488833-21-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for preparation of bis(thiohydrazide) derivs. used as Taxol enhancers)


RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 488833-21-2 CAPLUS

CN Propanedioic acid, 1,3-bis[2-(2-methylphenyl)-2-(phenylthioxomethyl)hydrazide] (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:818151 CAPLUS

DOCUMENT NUMBER: 139:323341

TITLE: Preparation of thiobenzoylhydrazide derivatives as taxol enhancers for treatment of cancer

INVENTOR(S): Koya, Keizo; Sun, Lijun; Chen, Shoujun; Tatsuta, Noriaki; Wu, Yaming; Ono, Mitsunori

PATENT ASSIGNEE(S): Synta Pharmaceuticals Corp., USA

SOURCE: U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Ser. No. 193,075.

CODEN: USXXCO

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 20030195258	A1	20031016	US 2003-345885	20030115
US 6924312	B2	20050802		
US 20030045518	A1	20030306	US 2002-193639	20020710
US 6762204	B2	20040713		
US 20030119914	A1	20030626	US 2002-193075	20020710

US 6800660	B2	20041005		
EP 1731148	A1	20061213	EP 2006-19066	20020710
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,				
LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK, RO, SI				
ZA 2004001051	A	20050622	ZA 2004-1051	20040209
ZA 2004001054	A	20050622	ZA 2004-1054	20040209
US 20040235909	A1	20041125	US 2004-803798	20040318
US 7001923	B2	20060221		
US 20050009920	A1	20050113	US 2004-846152	20040514
US 7037940	B2	20060502		
US 20060116374	A1	20060601	US 2005-244427	20051005
US 7368473	B2	20080506		
US 20060122183	A1	20060608	US 2005-244324	20051005
US 7345094	B2	20080318		
US 20080214655	A1	20080904	US 2008-9641	20080118
US 20080242702	A1	20081002	US 2008-77729	20080320
PRIORITY APPLN. INFO.:			US 2001-304252P	P 20010710
			US 2002-361936P	P 20020306
			US 2002-361946P	P 20020306
			US 2002-193075	A2 20020710
			US 2002-193639	A2 20020710
			EP 2002-746947	A3 20020710
			US 2004-803798	A1 20040318
			US 2004-846152	A1 20040514
			US 2005-244324	A1 20051005
			US 2005-244427	A3 20051005
OTHER SOURCE(S):		MARPAT 139:323341		
GI				




AB The title compds. I [wherein Y = a single bond, phenylene, or (un)substituted hydrocarbyl, etc.; R1 and R2 = independently (un)substituted aryl; R3-R6 = independently H, (un)substituted aliphatic group, or aryl; Z = O or S; etc.] and pharmaceutically acceptable salts thereof are prepared as taxol enhancers for treatment of cancer. For example, the compound II was prepared in a multi-step synthesis. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of I in combination with taxol or an analog of taxol. II showed synergistic anticancer activity with paclitaxel in rat.

IT 488833-02-9P 488833-21-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of thiobenzoylhydrazide derivs. as taxol enhancers for treatment of cancer)


RN 488833-02-9 CAPLUS

CN Propanedioic acid, 1,3-bis[2-[(2,5-dimethylphenyl)thioxomethyl]-2-methylhydrazide] (CA INDEX NAME)



RN 488833-21-2 CAPLUS

CN Propanedioic acid, 1,3-bis[2-(2-methylphenyl)-2-(phenylthioxomethyl)hydrazide] (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 16:05:32 ON 16 SEP 2009)

FILE 'REGISTRY' ENTERED AT 16:06:08 ON 16 SEP 2009

L1 STRUCTURE UPLOADED

L2 4 S L1 SSS

FILE 'CAPLUS' ENTERED AT 16:06:35 ON 16 SEP 2009

L3 16 S L2

L4 15 S L3 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)

L5 15 DUP REM L4 (0 DUPLICATES REMOVED)

=> file medline embase biosis

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
95.06	95.76

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-12.30	-12.30

CA SUBSCRIBER PRICE

FILE 'MEDLINE' ENTERED AT 16:08:19 ON 16 SEP 2009

FILE 'EMBASE' ENTERED AT 16:08:19 ON 16 SEP 2009

Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:08:19 ON 16 SEP 2009

Copyright (c) 2009 The Thomson Corporation

=> s l2  
L6 0 L2

=> s l2<chem>

SmartSELECT INITIATED  
New TRANSFER and ANALYZE Commands Now Available  
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.45	99.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-12.30

FILE 'REGISTRY' ENTERED AT 16:08:29 ON 16 SEP 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

SET SMARTSELECT ON  
SET COMMAND COMPLETED

SEL L2 1- CHEM  
L7 SEL L2 1- CHEM : 5 TERMS

SET SMARTSELECT OFF  
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	15.08	114.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-12.30

FILE 'MEDLINE' ENTERED AT 16:08:30 ON 16 SEP 2009

FILE 'EMBASE' ENTERED AT 16:08:30 ON 16 SEP 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:08:30 ON 16 SEP 2009  
Copyright (c) 2009 The Thomson Corporation

S L7  
L8 0 L7

=> d his

(FILE 'HOME' ENTERED AT 16:05:32 ON 16 SEP 2009)

FILE 'REGISTRY' ENTERED AT 16:06:08 ON 16 SEP 2009  
L1 STRUCTURE UPLOADED  
L2 4 S L1 SSS

FILE 'CAPLUS' ENTERED AT 16:06:35 ON 16 SEP 2009

L3 16 S L2  
L4 15 S L3 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)  
L5 15 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:08:19 ON 16 SEP 2009  
L6 0 S L2

FILE 'REGISTRY' ENTERED AT 16:08:29 ON 16 SEP 2009  
SET SMARTSELECT ON  
L7 SEL L2 1- CHEM : 5 TERMS  
SET SMARTSELECT OFF

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:08:30 ON 16 SEP 2009  
L8 0 S L7

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.21	117.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-12.30

STN INTERNATIONAL LOGOFF AT 16:08:43 ON 16 SEP 2009